Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers Valued at Over $245 Million: A Detailed Look
Cosmos Health’s New Anticancer Drugs: A Game-Changer in Cancer Treatment Cosmos Health Inc., a leading global healthcare group, recently made headlines with its announcement of securing buy-out rights and exclusive licensing for two innovative anticancer drugs. These drugs, developed through groundbreaking oncology research, will primarily target prostate, ovarian, and colorectal cancers. Both therapies are protected…